文献速递艾滋病与性传播感染

病毒学终点的定义改善基于分析性抗逆转录病毒治疗中断的HIV治愈策略设计

Definition of Virological Endpoints Improving the Design of HIV Cure Strategies Using Analytical Antiretroviral Treatment Interruption.
PubMed 文献 · Clin Infect Dis · 2024-01-01

该研究分析3项试验中235名HIV感染者的分析性治疗中断(ATI)期病毒动力学,比较时间相关与病毒载量幅度相关病毒学标准。结果显示nAUC与病毒设定点的相关性最强(>0.70),并建议ATI期>12周、定期监测及以10 000 copies/mL作为病毒学ART重启标准。

要点

  • nAUC与病毒设定点相关性最强,相关系数>0.70。
  • 病毒学ART重启标准为连续2次检测>100 000 copies/mL。
  • 建议ATI期>12周并定期监测,以10 000 copies/mL作为重启阈值。

核心结论

  • 结果与共识建议一致,强调ATI期>12周、定期监测及以10 000 copies/mL作为病毒学ART重启标准,以限制患者风险并保留nAUC作为设定点的最佳替代指标。

研究设计与样本

  • 分析3项试验中235名HIV感染者在ATI期的病毒动力学,描述时间相关与病毒载量幅度相关病毒学标准,并用Spearman相关分析寻找设定点的替代终点及最佳病毒学ART重启标准。

主要发现

  • 各试验间病毒学标准的比较显示其强烈依赖ATI设计。
  • 各试验间发现相似相关性,nAUC与设定点相关性最强,相关系数>0.70。
  • 病毒学ART重启标准要求连续2次检测>100 000 copies/mL。

关键数值与推荐

  • nAUC与设定点的相关系数>0.70。
  • 病毒学ART重启标准为连续2次检测>100 000 copies/mL。
  • 建议ATI期>12周并定期监测。
  • 建议病毒学ART重启标准为10 000 copies/mL。

临床怎么用

  • 作者建议ATI期>12周并定期监测,病毒学ART重启标准采用10 000 copies/mL,以限制患者风险并保留nAUC作为设定点的最佳替代指标。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Analytical treatment interruption (ATI) is the gold standard in HIV research for assessing the capability of new therapeutic strategies to control viremia without antiretroviral treatment (ART). The viral setpoint is commonly used as endpoint to evaluate their efficacy. However, in line with recommendations from a consensus meeting, to minimize the risk of increased viremia without ART, trials often implement short ATI phases and stringent virological ART restart criteria. This approach can limit the accurate observation of the setpoint. METHODS: We analyzed viral dynamics in 235 people with HIV from 3 trials, examining virological criteria during ATI phases. Time-related (eg time to rebound, peak, and setpoint) and viral load magnitude-related criteria (peak, setpoint, and time-averaged AUC [nAUC]) were described. Spearman correlations were analyzed to identify (1) surrogate endpoints for setpoint and (2) optimal virological ART restart criteria mitigating the risks of ART interruption and the evaluation of viral control. RESULTS: Comparison of virological criteria between trials showed strong dependencies on ATI design. Similar correlations were found across trials, with nAUC the most strongly correlated with the setpoint, with correlations >0.70. A threshold >100 000 copies/mL for 2 consecutive measures is requested as a virological ART restart criterion. CONCLUSIONS: Our results are in line with recommendations and emphasize the benefits of an ATI phase >12 weeks, with regular monitoring, and a virological ART restart criterion of 10 000 copies/mL to limit the risk for patients while capturing enough information to keep nAUC as an optimal proxy to the setpoint.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Alexandre M, Prague M, Lhomme E, et al. Definition of Virological Endpoints Improving the Design of HIV Cure Strategies Using Analytical Antiretroviral Treatment Interruption. Clin Infect Dis. 2024. PMID: 38819800. doi:10.1093/cid/ciae235

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。